Galapagos NV reports results for the quarter ended in June - Earnings Summary

Lakefront Biotherapeutics NV

01/08/2024 22:51

* Galapagos NV  GLPG.AS  reported quarterly adjusted
earnings of
14 cents​​ per share for the quarter ended in June, higher than
the same quarter last year, when the company reported EPS of 8
cents.  The lone analyst forecast for the quarter was for a loss
of 21 cents per share. 
    * Revenue fell 48.1% to €77.87 million from a year ago;
analysts
expected €71.88 million. 
    * Galapagos NV's reported EPS for the quarter was 14 cents​.
    * The company reported quarterly net income of €8.99
million.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Galapagos NV is
€37.50 
This summary was machine generated from LSEG data August 1 at
09:51 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.21          0.14           Beat
 Mar. 31 2024      -0.14          1.37           Beat
 Dec. 31 2023      -3.93          2.39           Beat
 Sep. 30 2023      -0.96          0.39           Beat